AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01904136 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Transplantation
Description: Undergo allogeneic PBSC or bone marrow transplant
Study NCT01904136 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV
Study NCT01904136 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Given IV
Study NCT01904136 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT01904136 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan
Description: Given IV
Study NCT01904136 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate Mofetil
Description: Given PO
Study NCT01904136 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Natural Killer Cell Therapy
Description: Given IV
Study NCT01904136 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Peripheral Blood Stem Cell Transplantation
Description: Undergo allogeneic PBSC or bone marrow transplant
Study NCT01904136 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: Given IV and PO
Study NCT01904136 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Total-Body Irradiation
Description: Undergo TBI
Study NCT00356993 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine Replacement Therapy
Description: transdermal nicotine patch, nicotine gum, nicotine inhaler, nicotine lozenge
Study NCT00356993 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: behavioural intervention
Description: Smoking cessation counselling, relapse prevention strategies
Study NCT03607617 — intervention group
Intervention type: OTHER
Intervention: SDH Tool
Description: The SDH tool is embedded in the EMR to collect and act on individualized social determinants of health data.
Study NCT03912974 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Escitalopram
Description: see 'arm description'
Study NCT03912974 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral capsule
Description: see 'arm description'
Study NCT00548756 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Whole Brain Radiation Therapy
Description: Whole Brain Radiation Therapy. Total dose = 30 Gy over 12 fractions at 2.5Gy per fraction.
Study NCT00548756 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Observation
Description: Patients who did not receive whole brain radiation and develop recurrent disease shall receive treatment based on the number of lesions.
Study NCT00548756 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Questionnaire
Description: Questionnaire taking 40 minutes to complete.
Study NCT00548756 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Questionnaire
Description: Questionnaire taking 40 minutes to complete.
Study NCT05336981 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Low-Level Light Therapy
Description: The method consists of the application extraoral of low-intensity infrared laser in the major salivary glands-parotid, submandibular
Study NCT05336981 — intervention group
Intervention type: RADIATION
Group type: SHAM_COMPARATOR
Intervention: Low-Level Light Therapy
Description: The method consists of the application extraoral of low-intensity infrared laser in the major salivary glands-parotid, submandibular
Study NCT01338805 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BGG492
Study NCT04274062 — intervention group
Intervention type: PROCEDURE
Intervention: Integrated Nursing care of placenta previa
Description: Phase I :( preparation phase) Phase II: (Implementation phase) includes Preoperative care , intraoperative care and postoperative care by a nurse.~Phase III: (Evaluation phase)
Study NCT01597583 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Use of MobileMedMinder
Description: Use of an intervention to remind patients to take their medications.
Study NCT03416569 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: placebo skin patch + placebo capsule
Study NCT03416569 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine
Description: nicotine patch (7 mg/24 hrs) + placebo capsule
Study NCT03416569 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prazosin
Description: placebo patch (7 mg/24 hrs) + prazosin capsule (1 mg)
Study NCT03416569 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine + Prazosin
Description: nicotine patch (7 mg/24 hrs) + prazosin capsule (1 mg)
Study NCT01957592 — intervention group
Intervention type: OTHER
Intervention: No treatment given
Description: Patients will fill out a questionnaire by interview.
Study NCT04596098 — intervention group
Intervention type: OTHER
Intervention: Blood sampling
Description: During a care-related blood sampling, patient will provide additional blood sample for research purpuse.
Study NCT05096078 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Diet
Description: Special diet program for gestational diabetes
Study NCT05096078 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diet
Description: Special diet program for gestational diabetes
Study NCT05096078 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: The circuit exercise program will consist of a medium-intensity circuit training for 50 minutes, 3 days a week, detailing the main muscle groups of the patients (chest, back, biceps, triceps, deltoid, quadriceps, thigh and calf muscles). Exercise intensity will be monitored using Borg's scale of perceived exertion, with a target intensity of 12 to 14. 8 exercises will be given in a continuous, circuit-type manner with short 1-minute rests.
Study NCT04595942 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midodrine Hydrochloride Tablets
Description: Patients will be started on 5 mg Midodrine three times a day and after one week the dosage will be up-titrated to 10 mg three times a day and continued for 12 months. They will receive the medication at four-hour intervals upon rising in the morning (the last dose should not be taken later than 6 PM). In case of intolerance, the dosage will be reduced to 2.5 mg three times a day. Patients will also receive recommendations for lifestyle modifications including drinking 2 to 3 liters of fluid per day, daily consumption of 10 grams of salt, and practicing counter-pressure maneuvers (handgrip, arm-tensing, leg crossing and squatting).
Study NCT04595942 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fludrocortisone Acetate Tablets
Description: Patients will be started on 0.05 mg of fludrocortisone twice daily and after one week the dosage will be up-titrated to 0.1 mg fludrocortisone twice daily taken for 12 months. Patients will also receive recommendations for lifestyle modifications including drinking 2 to 3 liters of fluid per day, daily consumption of 10 grams of salt, and practicing counter-pressure maneuvers (handgrip, arm-tensing, leg crossing and squatting). In this arm, potassium levels will be checked 7-14 days after dose stabilization.
Study NCT04595942 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Lifestyle modification
Description: Patients will be recommended to drink 2 to 3 liters of fluid per day, consume 10 grams of salt per day, and practice counter-pressure maneuvers (handgrip, arm-tensing, leg crossing and squatting) for 12 months.
Study NCT04595942 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Lifestyle modification
Description: Patients will be recommended to drink 2 to 3 liters of fluid per day, consume 10 grams of salt per day, and practice counter-pressure maneuvers (handgrip, arm-tensing, leg crossing and squatting) for 12 months.
Study NCT04298099 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine
Description: Given the reproducible efficacy of the erector spinae plane block for thoracic procedures, this pilot study will recruit patients scheduled to undergo thoracic surgery with the adjunct of an erector spinae plane block for perioperative pain. Participants will be assigned sequentially to either ropivacaine 0.2% at 0.3ml/kg or ropivacaine 0.5% at 0.3ml/kg.
Study NCT03887247 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: E-mail Alert
Description: Encrypted email to the following providers: the patient's opioid prescriber(s), benzodiazepine prescriber(s), and/or primary care manager. If there is more than one provider, they are copied together on the same message. The email identifies the concurrent prescriptions, details the patient's prescription history, includes relevant VA/DoD guidelines, states the risk of concurrent prescribing to patient, and provides action steps and relevant resources. When multiple providers are involved, the message encourages the providers to coordinate with each other and provides provider contact information to facilitate this communication.
Study NCT01361958 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NOMAC
Study NCT02416713 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cellcontrol DriveID
Description: Technology that blocks incoming and outgoing calls and texts.
Study NCT02416713 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Education Only
Description: No active intervention, educational materials will be provided
Study NCT04470843 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetazolamide
Description: Being that adequate pain control is essential to recovery in the post-operative setting, efforts have been made to address this pain at its root. Prior studies have demonstrated that preoperative administration of acetazolamide decreased post-operative referred pain in the immediate post-surgical period.
Study NCT04470843 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Group 2 (placebo): Patients undergoing RALP with the peri-operative use of 10 mL normal saline as placebo.
Study NCT02424019 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ILUVIEN 0.19 MG
Study NCT04680793 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Rehabilitation
Description: The program takes place over a total period of 9 weeks: for 4 weeks they will be cared for two days a week, then after a week's break, for 4 weeks they will be cared for three days a week for a total of approximately 80 hours of care. The program is multidisciplinary and includes: balneotherapy, ergometry, occupational therapy, gymnastics, physiotherapy, walking, sophrology, yoga as well as different workshops for the therapeutic education of the patient led by several professionals (dieticians, physiotherapists, doctors, psychologists).
Study NCT03550053 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: 3D mandibular plate
Description: Patients will be randomly assigned to either have the mandibular plate bent before their surgery, using a 3D model of their mandible or have the mandibular plate bent during their surgery, which is standard of care.
Study NCT00970320 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pelvic floor muscle training
Description: 6 months of daily pelvic floor exercise treatment with regular follow up by specialist physiotherapist.
Study NCT01861639 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ineffective rTMS
Description: A 20Hz repetitive transcranial magnetic stimulation (rTMS) will be applied for 900 ms with an intensity of 90% of motor threshold. Active stimulation will be applied on the L-DLPFC compared to an ineffective stimulation.
Study NCT01861639 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: ineffective rTMS
Description: A 20Hz repetitive transcranial magnetic stimulation (rTMS) will be applied for 900 ms with an intensity of 90% of motor threshold. Active stimulation will be applied on the L-DLPFC compared to an ineffective stimulation.
Study NCT01861639 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: active TBS
Description: A continuous Theta-Burst Stimulation (cTBS) protocol will be applied over the L-DLPFC. Three stimuli at 50Hz, 80% of individual Motor Threshold will be repeated every 200ms for 40sec
Study NCT01861639 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham TBS
Description: A Sham stimulation will be applied over the L-DLPFC. a placebo coil will be used.
Study NCT01861639 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: fMRI
Description: Functional MRI data will be acquired during the performance of the memory task. Functional data will be acquired with a blood oxygenation level dependant (BOLD) contrast sensitive gradient echo, T2\*-weighted echo-planar imaging sequence
Study NCT01861639 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: fMRI
Description: Functional MRI data will be acquired during the performance of the memory task. Functional data will be acquired with a blood oxygenation level dependant (BOLD) contrast sensitive gradient echo, T2\*-weighted echo-planar imaging sequence
Study NCT01861639 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EEG
Description: EEG will be coupled with task performance in an event-related manner to be able to isolate brain activity of each type of stimuli presented. EEG imaging data will be acquired during the memory task.
Study NCT01861639 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: EEG
Description: EEG will be coupled with task performance in an event-related manner to be able to isolate brain activity of each type of stimuli presented. EEG imaging data will be acquired during the memory task.
Study NCT01861639 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Effective rTMS
Description: A 20Hz repetitive transcranial magnetic stimulation (rTMS) will be applied for 900 ms with an intensity of 90% of motor threshold. Active stimulation will be applied on the L-DLPFC compared to an effective stimulation.
Study NCT01861639 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Effective rTMS
Description: A 20Hz repetitive transcranial magnetic stimulation (rTMS) will be applied for 900 ms with an intensity of 90% of motor threshold. Active stimulation will be applied on the L-DLPFC compared to an effective stimulation.
Study NCT04460729 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capmatinib
Description: 400 mg administered orally twice daily
Study NCT03587779 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sevoflurane
Description: Throughout the study period, anesthesia is maintained with sevoflurane of age-corrected equivalent minimum alveolar concentration.
Study NCT03587779 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Desflurane
Description: Throughout the study period, anesthesia is maintained with desflurane of age-corrected equivalent minimum alveolar concentration.
Study NCT04212780 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Medtronic Summit Rechargable (RC)+S
Description: Dual channel closed-loop pulse generator with connection to both new DBS leads for deep stimulation of VIM vs VO
Study NCT04212780 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ipsilateral thalamic (VIM+VO) DBS
Description: Implantation of two new ipsilateral thalamic (VIM+VO) DBS
Study NCT04212780 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: standard ET DBS
Description: Single Lead VIM
Study NCT04212780 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ipsilateral VO
Description: second lead in the ipsilateral VO
Study NCT03089736 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Education
Description: Six education areas was offered: pain and pain physiology, pain medication, side effects and prevention of side effects, abuse of medications, sleep advice and advice on anxiety.
Study NCT03089736 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self Care
Description: The following instructions on self-care for pain relief: apply ice or crushed ice in the oral cavity, lubricating and antiseptic mouth rinses, pain relieving gel, tongue movements and gaps exercises. Prevention of dryness in the mouth and throat; saliva stimulants and saliva substitute agents in different preparations, increased measures of good oral hygiene. Physical activities and regular rest once to several times per day. Sleep restriction and measures to treat sleep disorders.
Study NCT03089736 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Treatment as usual (TAU)
Description: pharmacological treatment + advices
Study NCT03089736 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Treatment as usual (TAU)
Description: pharmacological treatment + advices
Study NCT00936962 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NeisVac C vaccine (12mth)
Description: NeisVac C Meningococcal C Conjugate vaccine given IM 0.5mL in the deltoid muscle at 12 mths of age
Study NCT00077597 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: epoetin
Description: 3 times a week iv, as prescribed.
Study NCT00077597 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methoxy polyethylene glycol-epoetin beta [Mircera]
Description: 0.4 micrograms/kg iv (starting dose) once every 2 weeks
Study NCT00345709 — intervention group
Intervention type: BEHAVIORAL
Intervention: Questionnaire
Description: 65 page questionnaire that contains questions about your ovarian cancer diagnosis, gynecologic history, family history, general medical history, and health risk factors.
Study NCT04634955 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: tranforaminal epidural injection
Description: tranforaminal epidural injection which is performed by fluoroscopic guidance
Study NCT05000099 — intervention group
Intervention type: OTHER
Intervention: video calls
Description: A tablet for video-calls will be available for patients and families. Two video-calls of maximum 15' will be organized every week; in addition, patients will be allowed to do video-call upon request. Video-calls will be performed using Skype or WhatsApp video or Face-time
Study NCT02960945 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CTP-543, 16 mg (2 x 8 mg tablet)
Study NCT02960945 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Jakafi 15Mg Tablet
Study NCT02743988 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxygen
Description: Adapt inspired oxygen to achieve desired SpO2 target range
Study NCT02743988 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxygen
Description: Adapt inspired oxygen to achieve desired SpO2 target range
Study NCT02028247 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Personalized Cognitive-behavioral therapy
Study NCT02028247 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard Practice Cognitive-behavioral therapy
Study NCT02028247 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Treatment as Usual
Study NCT03447275 — intervention group
Intervention type: OTHER
Intervention: Type 2 diabetes
Description: Test if patients with diabetes have different blood concentrations of vitamin biomarkers compared with control subjects and if vitamin levels in the patients will differ according to renal damage.
Study NCT03629899 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: RETINA IMPLANT Alpha AMS
Description: Implantation of the subretinal RETINA IMPLANT Alpha AMS
Study NCT02836041 — intervention group
Intervention type: BEHAVIORAL
Intervention: questionnaires
Description: Pre-hospital sleep questionnaire completed (Brief Infant Sleep Questionnaire (BISQ)7 in children 0-3 years old; Children's Sleep Habits Questionnaire (CSHQ)8 in children 4 years and older). Subsequent Day(s):~In-hospital sleep questionnaire completed between one and three times per subject (Sleep at MSK questionnaire (SAM), adapted from Sleep in a Children's Hospital (SinCH)9 by Dr. Lisa Meltzer). (Patients will be observed for up to 3 consecutive nights in total).
Study NCT02836041 — intervention group
Intervention type: DEVICE
Intervention: actigraph
Description: This device reliably measures sleep by monitoring the child's motion.
Study NCT03238807 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Human Chorionic Gonadotropin
Description: 500 IU of human Chorionic Gonadotropin
Study NCT03530436 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Native turmeric extract
Description: 207 mg curcumin
Study NCT03530436 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Native turmeric extract with 7-9% volatile turmeric oils
Description: 207 mg curcumin
Study NCT03530436 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Turmeric extract plus mixture of phytochemicals
Description: 207 mg curcumin
Study NCT03530436 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Cyclodextrin complex of curcuminoids
Description: 207 mg curcumin
Study NCT03530436 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Turmeric oleoresin
Description: 207 mg curcumin
Study NCT03530436 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Liposomal curcumin
Description: 207 mg curcumin
Study NCT03530436 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Phytosomal curcumin
Description: 207 mg curcumin
Study NCT03530436 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Micellar turmeric extract
Description: 207 mg curcumin
Study NCT02525081 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ramipril (ACE-inhibitor)
Description: up to 10 mg
Study NCT02525081 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: up to 10 mg